BioWorld Asia

May 5, 2010

Oxford Immunotec Raises $26M to Boost T-Cell Tests Worldwide

LONDON - Oxford Immunotec Ltd. raised $26 million in a fourth-round funding, which it said will enable it to increase sales of its T-cell diagnostic for tuberculosis and take the company through to profitability. (BioWorld International) Read More

Asian Pacific Biotechs Branch Out from Health to White Tech

Study Pinpoints Viral RNA Targets for Future Drugs

Huntington's Drug Snagged on Statistics; Another Trial Needed?

BIO in Chicago: BioWorld Waxes Nostalgic, Biotech Perseveres

Affimed Plans to Take Antibodies into Clinic with $26M Series C

Protox's $75M Kissei Deal May Set Stage for Larger Alliances

Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Illustration demonstrating gut-brain axis

CINP 2026: Gut microbiota could predict antidepressant response

BioWorld

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...

Black wavy lines forming an abstract sound wave.png

Deep brain stimulation from the shallows: tomorrow’s BCI technology?

BioWorld

Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...

Ascending BCI systems deepen national security, ethical concerns

BioWorld

Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...